Summarized by Masters of Longevity from Longevity Technology.
Discussion of why large pharma should prioritize regenerative approaches over merely slowing decline, profiling Novartis research strategy and translational priorities.
Key Takeaways
- Fiona Marshall oversees around 5,500 scientists across nine Novartis research sites, and she sits on the company’s Executive Committee.
- As one pharma attendee put it to me, why is someone like Fiona Marshall at a conference like this, rather than at a 10,000-delegate cancer congress?.
- Decades of focus on genetic risk, she explains, have delivered some very effective therapies – but have also shown that genetics is only one factor interacting with environment and lifestyle.
